(Q43742480)

26 November 2017

title

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy (English)

1 reference

26 November 2017

1 reference

Kyoichi Kaira

1

1 reference

26 November 2017

Toshiaki Takahashi

2

1 reference

26 November 2017

Haruyasu Murakami

3

1 reference

26 November 2017

Takehito Shukuya

4

1 reference

26 November 2017

Hirotsugu Kenmotsu

5

1 reference

26 November 2017

Akira Ono

6

1 reference

26 November 2017

Tateaki Naito

7

1 reference

26 November 2017

Asuka Tsuya

8

1 reference

26 November 2017

Yukiko Nakamura

9

1 reference

26 November 2017

Masahiro Endo

10

1 reference

26 November 2017

Haruhiko Kondo

11

1 reference

26 November 2017

Takashi Nakajima

12

1 reference

26 November 2017

Nobuyuki Yamamoto

13

1 reference

26 November 2017

publication date

23 February 2012

1 reference

International Journal of Clinical Oncology

26 November 2017

published in

1 reference

26 November 2017

volume

18

1 reference

26 November 2017

issue

3

1 reference

26 November 2017

page(s)

371-379

1 reference

Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Prognostic and predictive factors in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Sequential assembly of the nucleotide excision repair factors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Docetaxel in non-small cell lung cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0386-8

Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease

21 January 2018

1 reference

12 December 2020

ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival

1 reference

12 December 2020

Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.

1 reference

12 December 2020

Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer

1 reference

12 December 2020

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

1 reference

12 December 2020

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

1 reference

12 December 2020

10.1007/S10147-012-0386-8

Identifiers

DOI

1 reference

Dimensions Publication ID

26 November 2017

1006560287

0 references

1 reference